Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis

Last updated: December 28, 2015
Sponsor: ALK-Abelló A/S
Overall Status: Completed

Phase

3

Condition

Atopic Dermatitis

Dermatitis, Atopic

Skin Infections/disorders

Treatment

N/A

Clinical Study ID

NCT00310492
SHX0556
  • Ages 18-55
  • All Genders

Study Summary

This trial is performed to assess the efficacy and safety of ALK-depot SQ mites for treatment of atopic dermatitis

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Positive specific IgE to house dust mites

  • Atopic dermatitis according to Hanifin/Rajka

  • Chronic course of Atopic dermatitis

  • SCORAD larger than 25 points

Exclusion

Exclusion Criteria:

  • Erythrodermia

  • Syst.treatment with gcs or immunosuppressive agents in the prev.4 weeks

  • History of specific immunotherapy with mites

  • UV radiation

  • Group 4 topical corticosteroids (European classification)

Study Design

Total Participants: 154
Study Start date:
April 01, 2006
Estimated Completion Date:
November 30, 2009

Connect with a study center

  • Medizinische Hochschule Hannover, Klinik für Dermatologie und Venerologie

    Hannover, D-30449 Hannover
    Germany

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.